Give us a call 855.726.8479 | 412.246.9858

Press Releases

Upsher-Smith Laboratories, LLC Selects PANTHERx® Rare for the Distribution of TORPENZ™ (everolimus) Tablets

PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it was selected by Upsher-Smith Laboratories, LLC for the distribution of TORPENZ™ (everolimus) Tablets for...
Read More

PANTHERx® Rare Partnering with Gilead Sciences, Inc. for the Distribution of LIVDELZI®

PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it is partnering with Gilead Sciences, Inc. for the distribution of a novel selective peroxisome proliferator-activated...
Read More

PANTHERx® Rare Partnering with ITF Therapeutics LLC for U.S. Distribution of DUVYZAT™

PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it is partnering with ITF Therapeutics LLC for the U.S. distribution of DUVYZAT™ (givinostat), the first nonsteroidal...
Read More

PANTHERx® Rare Appoints Bansi Nagji as CEO; Rob Snyder appointed Executive Chair

PITTSBURGH – PANTHERx® Rare, one of the nation’s largest and fastest growing rare disease specialty pharmacies, today announced the appointment of Bansi Nagji as CEO effective August 1, 2024. In this role, Mr. Nagji will continue his existing service...
Read More

PANTHERx® Rare Pharmacy Wins Seventh Patient Choice Award

PITTSBURGH – For a seventh time, PANTHERx Rare has been recognized as the winner of the annual Independent Specialty Pharmacy Patient Choice Award™, with the announcement made at the Asembia Specialty Pharmacy Summit this week. Since 2016, the Managed...
Read More

PANTHERx® Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDI™ (mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients with WHIM Syndrome

PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, today announced it was selected by X4 Pharmaceuticals, Inc. for the distribution of XOLREMDI™ (mavorixafor), recently approved by the...
Read More
1 2 3 4 5 12